Curcumin-induced aurora-a suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs

Ching Shiun Ke, Hsiao Sheng Liu, Cheng Hsin Yen, Guan Cheng Huang, Hung Chi Cheng, Chi Ying F. Huang, Chun-Li Su

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Overexpression of oncoprotein Aurora-A increases drug resistance and promotes lung metastasis of breast cancer cells. Curcumin is an active anticancer compound in turmeric and curry. Here we observed that Aurora-A protein and kinase activity were reduced in curcumin-treated human breast chemoresistant nonmetastatic MCF-7 and highly metastatic cancer MDA-MB-231 cells. Curcumin acts in a similar manner to Aurora-A small interfering RNA (siRNA), resulting in monopolar spindle formation, S and G2/M arrest, and cell division reduction. Ectopic Aurora-A extinguished the curcumin effects. The anticancer effects of curcumin were enhanced by Aurora-A siRNA and produced additivity and synergism effects in cell division and monopolar phenotype, respectively. Combination treatment with curcumin overrode the chemoresistance to four Food and Drug Administration (FDA)-approved anticancer drugs (ixabepilone, cisplatin, vinorelbine, or everolimus) in MDA-MB-231 cells, which was characterized by a decrease in cell viability and the occurrence of an additivity or synergy effect. Ectopic expression of Aurora-A attenuated curcumin-enhanced chemosensitivity to these four tested drugs. A similar benefit of curcumin was observed in MCF-7 cells treated with ixabepilone, the primary systemic therapy to patients with invasive breast cancer (stages IIA-IIIB) before surgery. Antagonism effect was observed when MCF-7 cells were treated with curcumin plus cisplatin, vinorelbine or everolimus. Curcumin-induced enhancement in chemosensitivity was paralleled by significant increases (additivity or synergy effect) in apoptosis and cell cycle arrest at S and G2/M phases, the consequences of Aurora-A inhibition. These results suggest that a combination of curcumin with FDA-approved anticancer drugs warrants further assessment with a view to developing a novel clinical treatment for breast cancer.

Original languageEnglish
Pages (from-to)526-539
Number of pages14
JournalJournal of Nutritional Biochemistry
Volume25
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Curcumin
Cell Cycle Checkpoints
Cells
Defects
Pharmaceutical Preparations
Cell Division
MCF-7 Cells
United States Food and Drug Administration
Breast Neoplasms
Small Interfering RNA
Cisplatin
Aurora Kinase A
Curcuma
G2 Phase
Oncogene Proteins
Drug Resistance
Protein Kinases
Surgery
Cell Survival
Breast

Keywords

  • Aurora-A
  • Chemosensitivity
  • Curcumin
  • FDA-approved anticancer drugs
  • Mitotic defects

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Nutrition and Dietetics
  • Clinical Biochemistry

Cite this

Curcumin-induced aurora-a suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. / Ke, Ching Shiun; Liu, Hsiao Sheng; Yen, Cheng Hsin; Huang, Guan Cheng; Cheng, Hung Chi; Huang, Chi Ying F.; Su, Chun-Li.

In: Journal of Nutritional Biochemistry, Vol. 25, No. 5, 01.01.2014, p. 526-539.

Research output: Contribution to journalArticle

Ke, Ching Shiun ; Liu, Hsiao Sheng ; Yen, Cheng Hsin ; Huang, Guan Cheng ; Cheng, Hung Chi ; Huang, Chi Ying F. ; Su, Chun-Li. / Curcumin-induced aurora-a suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. In: Journal of Nutritional Biochemistry. 2014 ; Vol. 25, No. 5. pp. 526-539.
@article{f451bf434bf342a89f7ba99363a284d0,
title = "Curcumin-induced aurora-a suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs",
abstract = "Overexpression of oncoprotein Aurora-A increases drug resistance and promotes lung metastasis of breast cancer cells. Curcumin is an active anticancer compound in turmeric and curry. Here we observed that Aurora-A protein and kinase activity were reduced in curcumin-treated human breast chemoresistant nonmetastatic MCF-7 and highly metastatic cancer MDA-MB-231 cells. Curcumin acts in a similar manner to Aurora-A small interfering RNA (siRNA), resulting in monopolar spindle formation, S and G2/M arrest, and cell division reduction. Ectopic Aurora-A extinguished the curcumin effects. The anticancer effects of curcumin were enhanced by Aurora-A siRNA and produced additivity and synergism effects in cell division and monopolar phenotype, respectively. Combination treatment with curcumin overrode the chemoresistance to four Food and Drug Administration (FDA)-approved anticancer drugs (ixabepilone, cisplatin, vinorelbine, or everolimus) in MDA-MB-231 cells, which was characterized by a decrease in cell viability and the occurrence of an additivity or synergy effect. Ectopic expression of Aurora-A attenuated curcumin-enhanced chemosensitivity to these four tested drugs. A similar benefit of curcumin was observed in MCF-7 cells treated with ixabepilone, the primary systemic therapy to patients with invasive breast cancer (stages IIA-IIIB) before surgery. Antagonism effect was observed when MCF-7 cells were treated with curcumin plus cisplatin, vinorelbine or everolimus. Curcumin-induced enhancement in chemosensitivity was paralleled by significant increases (additivity or synergy effect) in apoptosis and cell cycle arrest at S and G2/M phases, the consequences of Aurora-A inhibition. These results suggest that a combination of curcumin with FDA-approved anticancer drugs warrants further assessment with a view to developing a novel clinical treatment for breast cancer.",
keywords = "Aurora-A, Chemosensitivity, Curcumin, FDA-approved anticancer drugs, Mitotic defects",
author = "Ke, {Ching Shiun} and Liu, {Hsiao Sheng} and Yen, {Cheng Hsin} and Huang, {Guan Cheng} and Cheng, {Hung Chi} and Huang, {Chi Ying F.} and Chun-Li Su",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jnutbio.2014.01.003",
language = "English",
volume = "25",
pages = "526--539",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Curcumin-induced aurora-a suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs

AU - Ke, Ching Shiun

AU - Liu, Hsiao Sheng

AU - Yen, Cheng Hsin

AU - Huang, Guan Cheng

AU - Cheng, Hung Chi

AU - Huang, Chi Ying F.

AU - Su, Chun-Li

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Overexpression of oncoprotein Aurora-A increases drug resistance and promotes lung metastasis of breast cancer cells. Curcumin is an active anticancer compound in turmeric and curry. Here we observed that Aurora-A protein and kinase activity were reduced in curcumin-treated human breast chemoresistant nonmetastatic MCF-7 and highly metastatic cancer MDA-MB-231 cells. Curcumin acts in a similar manner to Aurora-A small interfering RNA (siRNA), resulting in monopolar spindle formation, S and G2/M arrest, and cell division reduction. Ectopic Aurora-A extinguished the curcumin effects. The anticancer effects of curcumin were enhanced by Aurora-A siRNA and produced additivity and synergism effects in cell division and monopolar phenotype, respectively. Combination treatment with curcumin overrode the chemoresistance to four Food and Drug Administration (FDA)-approved anticancer drugs (ixabepilone, cisplatin, vinorelbine, or everolimus) in MDA-MB-231 cells, which was characterized by a decrease in cell viability and the occurrence of an additivity or synergy effect. Ectopic expression of Aurora-A attenuated curcumin-enhanced chemosensitivity to these four tested drugs. A similar benefit of curcumin was observed in MCF-7 cells treated with ixabepilone, the primary systemic therapy to patients with invasive breast cancer (stages IIA-IIIB) before surgery. Antagonism effect was observed when MCF-7 cells were treated with curcumin plus cisplatin, vinorelbine or everolimus. Curcumin-induced enhancement in chemosensitivity was paralleled by significant increases (additivity or synergy effect) in apoptosis and cell cycle arrest at S and G2/M phases, the consequences of Aurora-A inhibition. These results suggest that a combination of curcumin with FDA-approved anticancer drugs warrants further assessment with a view to developing a novel clinical treatment for breast cancer.

AB - Overexpression of oncoprotein Aurora-A increases drug resistance and promotes lung metastasis of breast cancer cells. Curcumin is an active anticancer compound in turmeric and curry. Here we observed that Aurora-A protein and kinase activity were reduced in curcumin-treated human breast chemoresistant nonmetastatic MCF-7 and highly metastatic cancer MDA-MB-231 cells. Curcumin acts in a similar manner to Aurora-A small interfering RNA (siRNA), resulting in monopolar spindle formation, S and G2/M arrest, and cell division reduction. Ectopic Aurora-A extinguished the curcumin effects. The anticancer effects of curcumin were enhanced by Aurora-A siRNA and produced additivity and synergism effects in cell division and monopolar phenotype, respectively. Combination treatment with curcumin overrode the chemoresistance to four Food and Drug Administration (FDA)-approved anticancer drugs (ixabepilone, cisplatin, vinorelbine, or everolimus) in MDA-MB-231 cells, which was characterized by a decrease in cell viability and the occurrence of an additivity or synergy effect. Ectopic expression of Aurora-A attenuated curcumin-enhanced chemosensitivity to these four tested drugs. A similar benefit of curcumin was observed in MCF-7 cells treated with ixabepilone, the primary systemic therapy to patients with invasive breast cancer (stages IIA-IIIB) before surgery. Antagonism effect was observed when MCF-7 cells were treated with curcumin plus cisplatin, vinorelbine or everolimus. Curcumin-induced enhancement in chemosensitivity was paralleled by significant increases (additivity or synergy effect) in apoptosis and cell cycle arrest at S and G2/M phases, the consequences of Aurora-A inhibition. These results suggest that a combination of curcumin with FDA-approved anticancer drugs warrants further assessment with a view to developing a novel clinical treatment for breast cancer.

KW - Aurora-A

KW - Chemosensitivity

KW - Curcumin

KW - FDA-approved anticancer drugs

KW - Mitotic defects

UR - http://www.scopus.com/inward/record.url?scp=84897964985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897964985&partnerID=8YFLogxK

U2 - 10.1016/j.jnutbio.2014.01.003

DO - 10.1016/j.jnutbio.2014.01.003

M3 - Article

VL - 25

SP - 526

EP - 539

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 5

ER -